Peak Serum is proud to announce its assistance in cancer research at The Scripps Research Institute. Peak Serum’s Fetal Bovine Serum was recently credited in one of the world’s leading cancer journals, Oncogene. In this publication, LTBP3 promotes early metastatic events during cancer cell dissemination, human tumor cell lines and culture conditions were routinely cultured in DMEM supplemented with 10% of Peak Serum’s Fetal Bovine Serum.
“Peak Serum is honored to be mentioned by The Scripps Research Institute in such a notable and impressive cancer journal, Oncogene,” says Tom Kutrubes, President, and CEO of Peak Serum. “We hope to continue helping researchers publish their work around the world.”
Click Here to read the entire article.
About The Scripps Research Institute
The Scripps Research Institute is a world leader in biomedical research – expanding the frontiers of knowledge, accelerating new treatments for disease and training the next generation of scientists in this critical work. This institute one of the world’s largest, private, non-profit research organizations — stands at the forefront of basic biomedical science, a vital segment of medical research that seeks to comprehend the most fundamental processes of life. For more information, click here.
Oncogene aims to make substantial advances that contribute to cancer by publishing outstanding research. Areas covered by Oncogene include, but are not limited to, the cellular and molecular biology of cancer including resistance to cancer therapies, and development of better approaches to improving survival. Across cancer biology, this publication has a broad remit encompassing the life sciences and biomedicine, from the most fundamental and theoretical work, through to translational, applied, and clinical research. Reviewing Editors are among the most respected and accomplished individuals in their fields – from genetics and structural biology, to function and mechanism. Visit https://www.nature.com/onc for more information.